Compare QUBT & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QUBT | STOK |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2019 | 2019 |
| Metric | QUBT | STOK |
|---|---|---|
| Price | $6.86 | $27.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | $18.67 | ★ $46.38 |
| AVG Volume (30 Days) | ★ 6.4M | 1.2M |
| Earning Date | 11-09-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 84.93 | ★ 92.73 |
| EPS | ★ N/A | N/A |
| Revenue | $682,000.00 | ★ $184,420,000.00 |
| Revenue This Year | $4,100.54 | N/A |
| Revenue Next Year | $74.60 | $45.99 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 82.84 | ★ 404.50 |
| 52 Week Low | $5.39 | $21.81 |
| 52 Week High | $14.45 | $40.22 |
| Indicator | QUBT | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 49.62 | 58.11 |
| Support Level | $6.13 | $24.21 |
| Resistance Level | $6.98 | $33.92 |
| Average True Range (ATR) | 0.42 | 1.16 |
| MACD | 0.05 | 0.28 |
| Stochastic Oscillator | 91.28 | 91.39 |
Quantum Computing Inc is an integrated photonics and non-linear quantum optics company to develop and deliver machines for quantum computing, reservoir computing, and remote sensing, imaging, and cybersecurity applications based on patented and proprietary photonics technology. Its products are designed to operate at room temperature and low power at an affordable cost. The Company's portfolio of core technologies and products offers capabilities in the areas of high-performance computing, artificial intelligence, and cybersecurity, as well as remote sensing applications.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.